Search

Your search keyword '"Altamura, A. C."' showing total 277 results
Start Over Author "Altamura, A. C."
277 results on '"Altamura, A. C."'

5. Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study

Author

Buoli, M., Cesana, Bruno Mario, Bolognesi, S., Fagiolini, A., Albert, U., Di Salvo, G., Maina, G., de Bartolomeis, A., Pompili, Maurizio, Palumbo, C., Bondi, E., Steardo, L., De Fazio, P., Amore, Filippo, Altamura, M., Bellomo, Alberto, Bertolino, A., Di Nicola, Marco, Di Sciascio, G., Fiorillo, A., Sacchetti, E., Sani, Gabriele, Siracusano, Andrea, Di Lorenzo, G., Tortorella, Antonio, Altamura, A. C., Dell'Osso, Bernardo Maria, Cesana B. M., Pompili M. (ORCID:0000-0001-6699-7980), Amore M., Bellomo A., Di Nicola M. (ORCID:0000-0001-7457-0426), Sani G. (ORCID:0000-0002-9767-8752), Siracusano A., Tortorella A., Dell'Osso B., Buoli, M., Cesana, Bruno Mario, Bolognesi, S., Fagiolini, A., Albert, U., Di Salvo, G., Maina, G., de Bartolomeis, A., Pompili, Maurizio, Palumbo, C., Bondi, E., Steardo, L., De Fazio, P., Amore, Filippo, Altamura, M., Bellomo, Alberto, Bertolino, A., Di Nicola, Marco, Di Sciascio, G., Fiorillo, A., Sacchetti, E., Sani, Gabriele, Siracusano, Andrea, Di Lorenzo, G., Tortorella, Antonio, Altamura, A. C., Dell'Osso, Bernardo Maria, Cesana B. M., Pompili M. (ORCID:0000-0001-6699-7980), Amore M., Bellomo A., Di Nicola M. (ORCID:0000-0001-7457-0426), Sani G. (ORCID:0000-0002-9767-8752), Siracusano A., Tortorella A., and Dell'Osso B.

Abstract

The purpose of the present study was to detect demographic and clinical factors associated with lifetime suicide attempts in Bipolar Disorder (BD). A total of 1673 bipolar patients from different psychiatric departments were compared according to the lifetime presence of suicide attempts on demographic/clinical variables. Owing to the large number of variables statistically related to the dependent variable (presence of suicide attempts) at the univariate analyses, preliminary multiple logistic regression analyses were realized. A final multivariable logistic regression was then performed, considering the presence of lifetime suicide attempts as the dependent variable and statistically significant demographic/clinical characteristics as independent variables. The final multivariable logistic regression analysis showed that an earlier age at first contact with psychiatric services (odds ratio [OR] = 0.97, p < 0.01), the presence of psychotic symptoms (OR = 1.56, p < 0.01) or hospitalizations (OR = 1.73, p < 0.01) in the last year, the attribution of symptoms to a psychiatric disorder (no versus yes: OR = 0.71, partly versus yes OR = 0.60, p < 0.01), and the administration of psychoeducation in the last year (OR = 1.49, p < 0.01) were all factors associated with lifetime suicide attempts in patients affected by BD. In addition, female patients resulted to have an increased association with life-long suicidal behavior compared to males (OR: 1.02, p < 0.01). Several clinical factors showed complex associations with lifetime suicide attempts in bipolar patients. These patients, therefore, require strict clinical monitoring for their predisposition to a less symptom stabilization. Future research will have to investigate the best management strategies to improve the prognosis of bipolar subjects presenting suicidal behavior.

Published
2021

16. Integrated treatment of schizophrenia

Author

Altamura, A. C., Fagiolini, A., Silvana Galderisi, Rocca, P., Rossi, A., Altamura, A. C, Fagiolini, A., Galderisi, Silvana, Rocca, P., and Rossi, A.

Subjects
Rehabilitative and psychosocial psychotherapy, Clinical Psychology, Psychiatry and Mental Health, Pharmacological treatment
Abstract

Psychosocial therapies play an important role in the treatment of schizophrenia. These therapies are aimed at improving the functioning of the patient in the community, which in turn can lead to clinical improvement, such as reduction in the number of relapses or hospitalizations. Substantial evidence supports the use of many psychosocial therapies in schizophrenia, including cognitive behavioral therapy, assertive community treatment, cognitive remediation and functional skills training. The customization of pharmacological therapy in schizophrenia, besides the experience of the clinician and individual preferences of the patient, should be based on three sets of objective data: 1) clinical predictors of response to therapy; 2) predictable side effects of therapy; 3) pharmacogenetic and pharmacogenomic data. It has been made a considerable effort to improve adherence to antipsychotic treatment through the development of drugs with better tolerability, in formulations that enable long-term administration of the drug, including injectable long-acting (depot) antipsychotics. In recent years the development of these formulations of atypical antipsychotics and the promising results obtained in clinical trials are changing the attitude toward these drugs, traditionally reserved for patients with repeated non-adherence to treatment.

Published
2015

20. Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disoder: A Prospective Observational Study

Author

Rovera, Chiara, primary, Mauri, Massimo C., additional, Chiara, Di Pace, additional, Paletta, Silvia, additional, Reggiori, Alessandra, additional, Ciappolino, Valentina, additional, Cattaneo, Dario, additional, Baldelli, Sara, additional, Clementi, Emilio, additional, and Altamura, Alfredo C., additional

Published
2017
Full Text
View/download PDF

34. Frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: psychotic clinical presentation

Author

Galimberti, D., Fenoglio, C., Serpente, M., Villa, C., Bonsi, R., Arighi, A., Fumagalli, G., Del Bo, R., Bruni, A. C., Anfossi, M., Clodomiro, A., Cupidi, C., Nacmis, B., Sorbi, S., IRENE PIACERI, Bagnoli, S., Bessi, V., Marcone, A., Cerami, C., Cappa, S. F., Filippi, M., Agosta, F., Magnani, G., Comi, G., Franceschi, M., Rainero, I., Giordana, M. T., Rubino, E., Ferrero, P., Rogaeva, E., Xi, Z., Confaloni, A., Piscopo, P., Bruno, G., Talarico, G., Cagnin, A., Clerici, F., Osso, B., Comi, G. P., Altamura, A. C., Mariani, C., Scarpini, E., Galimberti, D, Fenoglio, C, Serpente, M, Villa, C, Bonsi, R, Arighi, A, Fumagalli, G, Del Bo, R, Bruni, Ac, Anfossi, M, Clodomiro, A, Cupidi, C, Nacmis, B, Sorbi, S, Piaceri, I, Bagnoli, S, Bessi, V, Marcone, A, Cerami, C, Cappa, Sf, Filippi, M, Agosta, F, Magnani, G, Comi, G, Franceschi, M, Rainero, I, Giordana, Mt, Rubino, E, Ferrero, P, Rogaeva, E, Xi, Z, Confaloni, A, Piscopo, P, Bruno, G, Talarico, G, Cagnin, A, Clerici, F, Dell’Osso, B, Comi, Gp, Altamura, Ac, Mariani, C, and Scarpini, E

Published
2013

37. Progranulin Gene Variability and Plasma Levels in Bipolar Disorder and Schizophrenia

Author

Galimberti, Daniela, primary, Dell'Osso, Bernardo, additional, Fenoglio, Chiara, additional, Villa, Chiara, additional, Cortini, Francesca, additional, Serpente, Maria, additional, Kittel-Schneider, Sarah, additional, Weigl, Johannes, additional, Neuner, Maria, additional, Volkert, Juliane, additional, Leonhard, C., additional, Olmes, David G., additional, Kopf, Juliane, additional, Cantoni, Claudia, additional, Ridolfi, Elisa, additional, Palazzo, Carlotta, additional, Ghezzi, Laura, additional, Bresolin, Nereo, additional, Altamura, A. C., additional, Scarpini, Elio, additional, and Reif, Andreas, additional

Published
2012
Full Text
View/download PDF

41. May Non-antipsychotic Drugs Improve Cognition of Schizophrenia Patients?

Author

Buoli, M. and Altamura, A. C.

Subjects
*AMNESTIC mild cognitive impairment, *ANTIPSYCHOTIC agents, *NOOTROPIC agents, *MIRTAZAPINE, *LAMOTRIGINE, *DIAGNOSIS, ALTERNATIVE treatment for schizophrenia
Abstract

Rationale: Cognitive impairment in schizophrenia patients is associated with poor outcome and it represents one of main challenges of pharmacological treatment. Unfortunately, second-generation antipsychotics have not yielded the expected results in the improvement of these symptoms. Objective: The purpose of the present review paper is to summarize and discuss the available data about the efficacy of non-antipsychotic drugs in the treatment of cognitive symptoms of schizophrenia. Methods: A research in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while studies with schizoaffective patients have been excluded. Results: Several non-antipsychotic compounds have been tested with the purpose to improve cognitive symptoms in schizophrenia patients, but no molecule has a significant pro-cognitive activity. Conclusion: Available data do not support the superiority of non-antipsychotic drugs vs. placebo for cognitive enhancement in schizophrenia. Preliminary results indicate mirtazapine, mianserine, lamotrigine, tandospirone, cyproheptadine, valacyclovir and omega-3 fatty acids as the most promising compounds, however no definitive conclusions can be drawn in the light of small sample size studies. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

44. CLINICAL PHARMACOLOGY OF ATYPICAL ANTIPSYCHOTICS: AN UPDATE.

Author

Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., and Altamura, A. C.

Subjects
CLINICAL pharmacology, ANTIPSYCHOTIC agents, CLOZAPINE, RISPERIDONE, QUETIAPINE
Abstract

This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine. A summary of their acute pharmacokinetics properties are also reported. Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine. Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine. Actually lurasidone seems to be best in terms of minimizing unwanted alterations in body weight and metabolic variables. Therapeutic drug monitoring is not strictly necessary for all of the new antipsychotic drugs because there are no unequivocal data supporting a relationship between plasma drug levels and clinical outcomes or side effects. The exception can be represented by clozapine for which plasma levels of 350-420 ng/ml are reported to be associated with an increased probability of a good clinical response. Also for olanzapine an established therapeutic range (20-50 ng/ml) is proposed to yield an optimal response and minimize side effects. [ABSTRACT FROM AUTHOR]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results